fatigue; chest pain; myocarditis; this is a spontaneous report received from a contactable reporter(s) (other hcp) from the regulatory agency. regulatory number: gb-mhra-webcovid-202202171418412190-0g1cm. other case identifier(s): gb-mhra-adr 26613079. a 24 year-old male patient received bnt162b2 (comirnaty), administration date 10feb2022 (lot number: fl9994) at the age of 24 years as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history was not reported. concomitant medication(s) included: colchicine. vaccination history included: bnt162b2 (dose 1), for covid-19 immunisation; bnt162b2 (dose 2), for covid-19 immunisation. the following information was reported: myocarditis (hospitalization, medically significant) with onset 10feb2022, outcome "recovering", described as "myocarditis"; fatigue (hospitalization, medically significant), outcome "unknown", described as "fatigue"; chest pain (hospitalization, medically significant), outcome "unknown", described as "chest pain". the events "myocarditis", "fatigue" and "chest pain" were evaluated at the physician office visit. the patient underwent the following laboratory tests and procedures: sars-cov-2 test: (unspecified date) negative, notes: no - negative covid-19 test; troponin: (16feb2022) 9012, notes: 9012. therapeutic measures were taken as a result of myocarditis, fatigue, chest pain. no follow-up attempts are possible. no further information is expected

test name: covid-19 virus test; test result: negative ; comments: no - negative covid-19 test; test date: 20220216; test name: troponin; result unstructured data: test result:9012; comments: 9012

na

na